PART I ITEM 1. B USINESS Company Overview We are a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. On March 26, 2025, we announced that our lead product candidate, VYKAT TM XR (diazoxide choline) extended-release tablets, formerly known as DCCR, had been approved by the U.S. Food and Drug Administration (FDA). VYKAT XR is indicated to treat hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). On Apr...
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-25 | 2025-12-31 | 0001193125-26-071808 | EDGAR | 73K words |
| 2025-02-28 | 2024-12-31 | 0000950170-25-029545 | EDGAR | — |
| 2024-03-07 | 2023-12-31 | 0000950170-24-027500 | EDGAR | — |
| 2023-03-22 | 2022-12-31 | 0000950170-23-009211 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001564590-22-013023 | EDGAR | — |
| 2021-03-03 | 2020-12-31 | 0001564590-21-010569 | EDGAR | — |
| 2020-03-04 | 2019-12-31 | 0001564590-20-008705 | EDGAR | — |
| 2019-03-20 | 2018-12-31 | 0001564590-19-008508 | EDGAR | — |
| 2018-04-02 | 2017-12-31 | 0001193125-18-104048 | EDGAR | — |
| 2017-03-15 | 2016-12-31 | 0001628280-17-002603 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001193125-25-264941 | EDGAR | 51K words |
| 2025-08-06 | 2025-06-30 | 0000950170-25-104220 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0000950170-25-065675 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122276 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0000950170-24-092713 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-057109 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0000950170-23-060438 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039934 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019752 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023838 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001564590-22-028965 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001564590-22-019266 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-06 | 0001193125-26-142911 | EDGAR | 67K words |
| 2026-03-16 | 0001193125-26-107429 | EDGAR | — |
| 2026-02-26 | 0001193125-26-073209 | EDGAR | — |
| 2026-02-25 | 0001193125-26-071528 | EDGAR | — |
| 2026-01-23 | 0001193125-26-021229 | EDGAR | — |
| 2026-01-12 | 0001193125-26-009886 | EDGAR | — |
| 2025-11-12 | 0001193125-25-275674 | EDGAR | — |
| 2025-11-04 | 0001193125-25-264658 | EDGAR | — |
| 2025-10-14 | 0001193125-25-237854 | EDGAR | — |
| 2025-09-10 | 0001193125-25-199882 | EDGAR | — |
255 total filings indexed. 223 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001484565 |
| Ticker | SLNO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.soleno.life |
| Listed | 2014-11-13 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report